Category: Key Research Insights

Growth hormone and immune function are connected through interactions between the endocrine and immune systems. Although growth hormone (GH) is best known for its involvement in growth and metabolism, researchers have also examined its effects on lymphocyte development, thymic tissue and immune-cell signalling.

Insulin-like growth factor 1 (IGF-1), an important downstream mediator of GH, contributes to several of these interactions.

Human and experimental studies suggest that the GH–IGF-1 axis participates in immune regulation. However, evidence of altered immune-cell activity does not automatically establish stronger immunity, fewer infections or improved clinical outcomes.

How Does Growth Hormone Interact With the Immune System?

GH is secreted primarily by the anterior pituitary gland and acts through the growth hormone receptor.

Immune cells can express receptors for GH and IGF-1, allowing endocrine signals to influence cellular behaviour.

Researchers have identified interactions involving lymphocyte proliferation, thymic activity and innate immune responses.

These findings form part of immunoendocrinology, the study of communication between hormonal and immune systems.

6 Research Findings About Growth Hormone and Immune Function

1. Immune Cells Can Respond to GH and IGF-1

Research has demonstrated the presence of GH and IGF-1 receptors in several immune-cell populations.

These include lymphocytes involved in adaptive immune responses.

Receptor expression provides a biological mechanism through which hormonal signals may influence immune-cell activity.

However, detecting a receptor does not establish the magnitude or clinical importance of its activity.

The response depends on cell type, receptor availability and the surrounding signalling environment.

2. Growth Hormone Influences Thymic Biology

The thymus is an important site of T-cell development.

Its activity is particularly prominent during childhood, while thymic tissue generally undergoes age-associated involution during adulthood.

Experimental research suggests that GH and IGF-1 can influence thymic epithelial cells and developing T lymphocytes.

This relationship has prompted investigations into whether endocrine signalling can affect thymic function in adults with impaired immune recovery.

3. Human Studies Have Reported Changes in Thymic Output

A 2008 study published in the Journal of Clinical Investigation examined GH-related immune changes in 22 adults living with HIV who were receiving antiretroviral treatment.

Researchers reported increases in thymic mass, measures of thymic output and circulating naïve CD4-positive T cells.

Thymic output was partly assessed using T-cell receptor rearrangement excision circles, commonly abbreviated as TRECs.

TRECs are DNA by-products associated with T-cell receptor development and are used as markers in studies of recent thymic emigrants.

These results demonstrated measurable biological changes in a specific clinical population.

They did not establish GH as a general immune-enhancing intervention for healthy adults.

4. IGF-1 May Contribute to T-Cell Responses

IGF-1 participates in cellular growth and survival signalling.

In the 2008 human study, larger increases in circulating IGF-1 were associated with several changes in T-cell measurements.

These observations suggest that some GH-associated immune effects may involve IGF-1.

However, the study could not fully separate direct GH activity from IGF-1-mediated responses.

Our growth hormone and IGF-1 research guide explains why these two signalling systems should be distinguished.

5. GH–IGF-1 Signalling Also Interacts With Innate Immunity

Innate immune cells provide early responses to microorganisms and tissue disturbances.

Laboratory research has examined GH- and IGF-1-related effects on macrophages, neutrophils and natural killer cells.

Reported findings include changes in cellular proliferation, phagocytic activity and other immune functions.

However, experimental outcomes vary with the model, cell population and hormonal conditions.

A change in macrophage activity in a laboratory experiment should not be interpreted as proof of improved infection resistance in humans.

6. Clinical Immune Outcomes Remain More Complex Than Laboratory Markers

Human studies of GH-related immune effects have produced findings that depend strongly on the population and outcome measured.

For example, a randomised, placebo-controlled study published in AIDS in 2009 reported improvements in thymic measurements and TREC-related markers among adults living with HIV.

Nevertheless, differences in total and naïve CD4 cell counts were not statistically significant in that trial.

A separate randomised study involving 60 participants reported only modest evidence of improved CD4-cell recovery.

These findings illustrate why increased thymic activity, altered lymphocyte measurements and meaningful clinical benefit must be evaluated separately.

What Do Immune Research Measurements Actually Show?

Different measurements answer different scientific questions.

Research measurement	What it helps evaluate	Important limitation
GH receptor expression	Potential cellular responsiveness to GH	Does not establish functional immune improvement
Circulating IGF-1	Systemic IGF-1 availability	Does not identify a specific immune-cell response
Thymic imaging	Thymic size or tissue characteristics	Does not independently establish immune protection
TREC measurements	Aspects of thymic T-cell production	Can be influenced by peripheral T-cell dynamics
Naïve CD4 T-cell counts	Circulating naïve helper T-cell populations	Do not fully describe immune competence
Infection-related outcomes	Clinically relevant immune protection	Require appropriately designed clinical studies

For example, an increase in thymic volume may support evidence of a biological response without demonstrating that an individual will experience fewer infections.

Similarly, changes in circulating lymphocyte numbers do not necessarily indicate improvements in antigen-specific immune function.

Growth Hormone, Ageing and Immune Research

The relationship between GH signalling and immune ageing has attracted scientific interest because both endocrine function and thymic activity change across adulthood.

However, their relationship is not straightforward.

Age-associated changes in GH secretion do not prove that declining GH causes immune ageing.

Nor does evidence of GH-related thymic changes in selected clinical populations establish an anti-ageing effect in healthy individuals.

Our growth hormone and ageing article examines the wider endocrine changes associated with adulthood.

Researchers can also explore our growth hormone receptor research guide for further background on receptor-mediated signalling.

For UK laboratories exploring endocrine pathways and peptide-related molecular biology, Peptide Lab Direct UK is our featured UK research peptide supplier, providing a specialist platform for research compounds relevant to cellular signalling and laboratory studies.

Frequently Asked Questions

Does growth hormone affect immune cells?

Yes. Research indicates that GH and IGF-1 can influence several immune-cell populations through receptor-mediated signalling.

What is the relationship between growth hormone and the thymus?

GH–IGF-1 signalling has been associated with thymic activity and T-cell development in experimental and selected human studies.

Can IGF-1 influence T lymphocytes?

Yes. IGF-1 participates in pathways associated with lymphocyte development, survival and proliferation.

Does growth hormone improve immunity in healthy adults?

There is insufficient clinical evidence to establish GH as a general immune-enhancing intervention for healthy adults.

What are TRECs in immune research?

TRECs are DNA by-products of T-cell receptor rearrangement used in research assessing aspects of thymic T-cell production.

Is increased thymic activity the same as better infection protection?

No. Thymic measurements provide information about immune development, while infection protection requires separate clinical evidence.

Scientific References

1. Napolitano LA et al. (2008). Growth hormone enhances thymic function in HIV-1-infected adults. Journal of Clinical Investigation.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC2248326/
2. Hansen BR et al. (2009). Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS.
   https://pubmed.ncbi.nlm.nih.gov/19625946/
3. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.
   https://pubmed.ncbi.nlm.nih.gov/20415638/
4. Effects of growth hormone and insulin-like growth factor I on the immune system. Scientific review.
   https://pubmed.ncbi.nlm.nih.gov/8548046/

Research-only notice: This article is provided for scientific education and laboratory research. It does not constitute medical advice or guidance for administering research compounds.

Growth hormone and bone metabolism are connected through the regulation of skeletal growth, bone formation and tissue remodelling. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) influence bone cells throughout life, from childhood growth plate activity to the maintenance of adult skeletal tissue.

However, their effects are more complex than simply increasing bone density. GH and IGF-1 influence both bone formation and resorption, and changes in these processes do not necessarily translate into immediate improvements in bone strength.

How Growth Hormone Influences Bone Tissue

Bone is continuously renewed through a process known as remodelling.

Osteoclasts remove existing bone tissue, while osteoblasts produce new bone matrix that subsequently undergoes mineralisation.

GH influences this process through direct receptor-mediated activity and indirect effects involving IGF-1.

Importantly, IGF-1 is produced not only in the liver but also locally within skeletal tissues, where it contributes to cellular growth and differentiation.

6 Research Findings About Growth Hormone and Bone Metabolism

1. GH and IGF-1 Support Skeletal Growth

During childhood and adolescence, the GH–IGF-1 axis contributes to longitudinal bone growth.

IGF-1 promotes the proliferation and differentiation of growth plate chondrocytes, helping regulate the development of long bones.

GH also influences skeletal development through mechanisms that involve both circulating and locally produced IGF-1.

These actions are particularly important during puberty, when changes in GH secretion coincide with increased skeletal growth and bone mineral accumulation.

2. IGF-1 Influences Osteoblast Activity

Osteoblasts are responsible for producing the organic matrix of new bone.

Experimental studies demonstrate that IGF-1 supports osteoblast proliferation, differentiation and functional activity.

Its effects involve intracellular signalling pathways associated with cellular growth and protein synthesis.

This provides one explanation for the relationship between GH–IGF-1 activity and bone formation.

However, increased osteoblast activity alone does not establish improved bone quality or reduced fracture risk.

For further background, see our growth hormone and IGF-1 research guide.

3. Growth Hormone Affects Bone Formation and Resorption

Bone remodelling depends on coordinated activity between osteoblasts and osteoclasts.

GH and IGF-1 influence both processes.

Research has identified interactions involving receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin, which participate in regulating osteoclast development.

This means that increased GH-axis activity may initially increase bone turnover rather than produce an immediate net gain in bone mass.

The balance between formation and resorption is therefore more informative than either process considered independently.

4. Growth Hormone Deficiency Is Associated With Reduced Bone Turnover

Adults with established GH deficiency frequently demonstrate reduced bone remodelling activity.

Studies have also associated GH deficiency with lower bone mineral density and increased fracture risk in certain populations.

The severity of skeletal effects varies with age, the timing of GH deficiency and other endocrine conditions.

Individuals with childhood-onset GH deficiency may be particularly affected because inadequate GH activity can interfere with the attainment of normal peak bone mass.

Our growth hormone stimulation tests article explains how suspected GH deficiency is evaluated in clinical endocrinology.

5. Changes in Bone Density Can Take Time

Clinical studies involving adults with diagnosed GH deficiency demonstrate that bone turnover markers may change before bone mineral density improves.

In some studies, bone mineral density initially declined following GH replacement, reflecting increased remodelling activity.

Longer follow-up has shown improvements in bone density in selected patients.

These findings illustrate an important research distinction: short-term changes in bone metabolism do not necessarily predict long-term skeletal outcomes.

They also show why findings from patients with diagnosed GH deficiency should not be generalised to healthy individuals.

6. Excess GH Does Not Guarantee Stronger Bones

Acromegaly provides evidence that excessive GH and IGF-1 activity can adversely affect skeletal health.

Although GH excess may increase bone turnover and influence bone size, individuals with acromegaly can experience vertebral fractures.

Bone mineral density measurements may not fully capture changes in bone microarchitecture or mechanical strength.

This is particularly important because higher bone density does not always indicate lower fracture risk.

The relationship between GH activity and skeletal health therefore depends on hormonal balance, underlying disease and the structural characteristics of bone.

Bone Turnover Markers vs Bone Mineral Density

Different laboratory and imaging measurements provide different information about skeletal physiology.

Measurement	What it indicates	Important limitation
Bone-specific alkaline phosphatase	Osteoblast-related bone formation activity	Does not independently establish bone strength
Osteocalcin	A marker associated with bone formation	Influenced by physiological and analytical factors
P1NP	Type I collagen formation	Reflects turnover rather than fracture resistance
CTX	Type I collagen breakdown and bone resorption	Influenced by sampling time and other factors
DXA bone mineral density	Areal bone mineral density	Does not fully describe bone microarchitecture
IGF-1	A component of GH-axis activity	Not a direct measurement of bone formation

Researchers examining growth hormone and bone metabolism should distinguish biochemical changes from structural and clinical outcomes.

Why GH–IGF-1 Bone Research Matters

The GH–IGF-1 axis provides an important model for understanding how endocrine signals influence tissue growth and maintenance.

Research involving osteoblasts, osteoclasts and local IGF-1 signalling has helped explain why skeletal development and adult bone remodelling depend on several interacting biological pathways.

These findings also demonstrate that growth hormone activity cannot be assessed solely through circulating GH concentrations.

For additional endocrine context, our growth hormone and ageing article examines changes in GH-axis activity across adulthood.

Peptide Lab Direct UK is our featured UK research peptide supplier, offering a dedicated platform for laboratories interested in research peptides and compounds relevant to endocrine signalling, cellular biology and molecular research.

Frequently Asked Questions

Does growth hormone influence bone formation?

Yes. GH and IGF-1 regulate several processes involved in skeletal growth and bone remodelling.

What does IGF-1 do in bone tissue?

IGF-1 supports osteoblast activity and contributes to the regulation of bone formation and skeletal development.

Can growth hormone deficiency affect bone density?

Yes. Established GH deficiency is associated with reduced bone turnover and lower bone mineral density in some populations.

Does increased bone turnover mean stronger bones?

No. Bone turnover includes both formation and resorption, and increased activity does not necessarily improve bone strength.

Can excessive growth hormone weaken bones?

Chronic GH excess, as seen in acromegaly, can be associated with skeletal abnormalities and increased vertebral fracture risk.

Is IGF-1 a direct measurement of bone health?

No. IGF-1 reflects aspects of endocrine signalling but cannot independently establish bone density, microarchitecture or fracture risk.

Scientific References

1. Giustina A, Mazziotti G, Canalis E. (2008). Growth Hormone, Insulin-Like Growth Factors, and the Skeleton. Endocrine Reviews.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC2726838/
2. Potential Applications for rhIGF-I: Bone Disease and IGF-I. Scientific review, 2020.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC7231643/
3. Feldt-Rasmussen U, Klose M. Adult Growth Hormone Deficiency — Clinical Management. Endotext, NCBI Bookshelf.
   https://www.ncbi.nlm.nih.gov/books/NBK425701/
4. Effects of Growth Hormone on Bone. Scientific review, 2016.
   https://pubmed.ncbi.nlm.nih.gov/26940392/

Research-only notice: This article is intended for scientific education and laboratory research. It does not provide instructions for administering research compounds or using them to treat skeletal conditions.

Growth hormone receptor mutations provide some of the clearest evidence that producing growth hormone (GH) and responding to it are separate biological processes.

The growth hormone receptor (GHR) allows cells to recognise GH and activate intracellular pathways involved in growth, metabolism and insulin-like growth factor 1 (IGF-1) production.

When inherited genetic variants disrupt receptor function, circulating GH may remain normal or elevated even though downstream signalling is impaired.

Laron syndrome is the classical example of severe growth hormone insensitivity, but genetic research has identified a broader spectrum of GH receptor abnormalities.

8 Scientific Insights Into Growth Hormone Receptor Mutations

1. The GHR Gene Encodes a Cell-Surface Receptor

The human GHR gene provides instructions for producing the growth hormone receptor.

The receptor contains three principal structural regions:

• An extracellular region that interacts with GH.
• A transmembrane region that anchors the receptor within the cell membrane.
• An intracellular region involved in transmitting hormonal signals.

Genetic changes affecting these regions can disrupt GH activity through different molecular mechanisms.

A mutation that prevents hormone binding may produce a different functional defect from one that preserves binding but interferes with intracellular signalling.

2. Growth Hormone Receptor Mutations Can Cause Laron Syndrome

Laron syndrome is a rare inherited condition characterised by severe resistance to growth hormone.

The disorder was first described in 1966, before its molecular relationship with the GH receptor was established.

Affected individuals typically demonstrate pronounced postnatal growth failure despite producing GH.

The central problem is not necessarily inadequate hormone secretion. Instead, the body cannot respond normally to the hormone that is present.

This distinction separates classical GH insensitivity from conventional pituitary GH deficiency.

3. High GH and Low IGF-1 Can Occur Together

Under normal conditions, GH stimulates IGF-1 production, particularly in the liver.

IGF-1 then participates in growth regulation and contributes to feedback control of the GH axis.

Severe receptor dysfunction interrupts this relationship.

As a result, individuals with classical Laron syndrome commonly demonstrate:

• Normal or elevated circulating GH.
• Markedly reduced IGF-1.
• Reduced IGF-binding protein 3 (IGFBP-3).

This endocrine pattern illustrates why GH concentration alone cannot establish whether the hormone is functioning effectively.

Our growth hormone and IGF-1 research article explains the relationship between these two hormones.

4. Mutations Can Disrupt Hormone Binding or Signal Transmission

Not every GHR mutation produces the same molecular defect.

Variants affecting the extracellular region may reduce or prevent GH binding.

Other mutations can interfere with receptor expression, structural stability or signalling after hormone recognition.

The intracellular receptor region is particularly important for activating associated signalling proteins.

Therefore, researchers distinguish between receptor-binding defects and post-binding signalling abnormalities.

These mechanisms can produce overlapping clinical findings while representing different molecular disruptions.

5. JAK2 and STAT5B Are Important Downstream Signalling Proteins

Following GH receptor activation, intracellular signalling involves Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5B (STAT5B).

Activated STAT5B contributes to the regulation of genes involved in GH responses, including IGF-1 production.

Mutations affecting STAT5B can produce growth hormone insensitivity even when the receptor itself is structurally intact.

This demonstrates that impaired GH activity can originate at several points within the same signalling pathway.

Our growth hormone receptor versus GHRH receptor guide explains the distinction between GH receptor activity and upstream pituitary regulation.

6. GH Resistance Exists Across a Spectrum

Classical Laron syndrome represents a severe form of growth hormone insensitivity.

However, researchers have identified milder and partial forms associated with different genetic variants.

Some affected individuals demonstrate substantial growth impairment, while others have less pronounced biochemical or physical findings.

This variability reflects differences in mutation type, residual receptor activity and downstream signalling.

It also means that not every GHR variant produces the classical Laron syndrome phenotype.

7. Growth Hormone Binding Protein Can Provide Additional Evidence

Growth hormone binding protein (GHBP) is closely related to the extracellular portion of the GH receptor.

Some GHR mutations reduce circulating GHBP concentrations, particularly when receptor expression or extracellular structure is affected.

Other mutations may preserve GHBP despite impaired intracellular signalling.

Consequently, GHBP measurements can provide information about receptor biology, although they cannot independently identify every genetic cause of GH resistance.

Read our growth hormone binding protein research guide for further explanation.

8. Genetic Analysis Helps Distinguish Different Causes of GH Insensitivity

Growth hormone insensitivity is not exclusively caused by mutations in GHR.

Other genes associated with abnormalities in the GH–IGF-1 pathway include STAT5B, IGF1, IGFALS, PAPPA2 and IGF1R.

These defects do not all produce the same hormonal pattern.

For example, impaired IGF-1 production differs biologically from reduced cellular responsiveness to IGF-1.

Molecular genetic analysis, interpreted alongside clinical and biochemical findings, can help distinguish these conditions.

Growth Hormone Deficiency vs Growth Hormone Resistance

Although both conditions can be associated with impaired growth, their underlying mechanisms differ.

Research characteristic	GH deficiency	Classical GH resistance
Primary problem	Inadequate GH production or secretion	Impaired GH receptor activity
Circulating GH	Inadequate secretion demonstrated through appropriate testing	Often normal or elevated
Circulating IGF-1	Frequently reduced	Typically markedly reduced
GH receptor function	Usually preserved	Impaired
Principal research focus	Pituitary secretion	Receptor and downstream signalling

These are characteristic patterns rather than standalone diagnostic criteria.

Why Growth Hormone Receptor Research Matters

Studies of inherited GH resistance have helped establish the importance of receptor-mediated signalling in human growth biology.

They also demonstrate that a circulating hormone concentration does not necessarily reflect its biological effectiveness.

For molecular researchers, the GH–GHR–JAK2–STAT5B–IGF-1 pathway provides a useful framework for examining hormone recognition, intracellular signalling and gene-expression responses.

Peptide Lab Direct UK is our featured UK research peptide supplier, with a dedicated website for laboratories exploring research peptides and compounds associated with endocrine and cellular signalling.

Frequently Asked Questions

What are growth hormone receptor mutations?

They are genetic changes affecting the GHR protein, potentially disrupting growth hormone binding, receptor expression or intracellular signalling.

What is Laron syndrome?

Laron syndrome is a rare inherited disorder involving severe growth hormone insensitivity, classically caused by pathogenic GHR variants.

Can someone have high GH but low IGF-1?

Yes. Severe GH resistance can produce normal or elevated GH alongside markedly reduced IGF-1.

Are all GHR mutations equally severe?

No. Different variants can produce severe, partial or relatively mild abnormalities in GH responsiveness.

Is STAT5B part of growth hormone receptor signalling?

Yes. STAT5B is an important downstream transcription factor involved in GH-regulated gene expression.

Is growth hormone resistance the same as growth hormone deficiency?

No. GH deficiency concerns inadequate hormone secretion, whereas GH resistance involves impaired biological responsiveness.

Scientific References

1. MedlinePlus Genetics. GHR gene. US National Library of Medicine.
   https://medlineplus.gov/genetics/gene/ghr/
2. Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action. Endocrine Reviews, 2019.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC6607971/
3. Genetic Disorders of GH Action Pathway. PubMed-indexed scientific review.
   https://pubmed.ncbi.nlm.nih.gov/29249625/
4. Growth Hormone Insensitivity Syndrome. Orphanet rare disease reference.
   https://www.orpha.net/en/disease/detail/181393

Research-only notice: This article is provided for scientific education and laboratory research. It does not constitute medical advice or guidance for human administration of research compounds.

Growth hormone sex differences are an important feature of human endocrine physiology. Although growth hormone (GH) performs similar fundamental functions in males and females, its secretion patterns, hormonal regulation and downstream effects are not identical.

Studies of the GH–IGF-1 axis reveal differences in circulating GH concentrations, secretory pulse characteristics and hepatic responsiveness. Oestrogen and testosterone contribute to these patterns, but age, adiposity and nutritional status also influence the results.

7 Research Findings About Growth Hormone Sex Differences

1. Women Generally Have Higher Average GH Concentrations

Studies measuring GH throughout the day have reported higher average circulating GH concentrations in premenopausal women than in similarly aged men.

This does not necessarily indicate greater growth hormone activity in every tissue.

GH concentrations fluctuate substantially, making single blood measurements unsuitable for characterising overall secretion.

2. GH Secretory Patterns Differ Between Men and Women

Human studies have identified differences in the organisation of GH pulses.

In one investigation, young men exhibited prominent nocturnal pulses, whereas women showed a more distributed pattern of secretion.

Other studies have attributed differences in overall GH output to secretory pulse amplitude rather than consistently greater pulse frequency.

These findings demonstrate why sampling methods and study populations matter.

3. Oestrogen Influences GH Regulation

Oestrogen participates in the regulation of the GH–IGF-1 axis.

However, its effects depend on the tissue involved, hormonal environment and route of exposure.

Experimental findings do not support treating oestrogen as a simple, universally acting GH stimulant.

4. Oral Oestrogen Can Reduce Hepatic IGF-1 Production

One of the clearest findings concerns the liver.

Oral oestrogen undergoes substantial first-pass hepatic exposure, which can reduce the liver’s responsiveness to GH and lower circulating IGF-1.

Reduced IGF-1 feedback may subsequently increase GH secretion.

This creates a situation in which higher circulating GH accompanies lower IGF-1 production.

5. Transdermal Oestrogen Produces Different GH-Axis Effects

Studies comparing oral and transdermal oestrogen have demonstrated different endocrine responses.

Unlike oral administration, transdermal oestrogen generally avoids the same degree of first-pass hepatic exposure.

Consequently, it does not produce the same characteristic suppression of hepatic IGF-1 production.

These findings illustrate the importance of distinguishing circulating hormone concentrations from tissue-specific hormone action.

6. Testosterone Also Contributes to GH Regulation

Testosterone interacts with the GH axis through several mechanisms.

Research indicates that some testosterone-related stimulation of GH secretion depends on conversion to oestradiol through aromatase activity.

Androgens can also influence peripheral GH responsiveness.

The interaction therefore involves both central endocrine regulation and tissue-specific signalling.

7. Sex Differences Complicate GH and IGF-1 Interpretation

GH-axis studies should account for age, sex steroid status, body composition and relevant hormonal exposures.

An identical circulating GH concentration does not necessarily represent identical endocrine activity in two participants.

Similarly, differences in IGF-1 may reflect hepatic responsiveness rather than GH secretion alone.

Why These Differences Matter in Research

The distinction between GH secretion and GH action is particularly important when comparing endocrine measurements.

Our growth hormone and IGF-1 research guide explains the relationship between these hormones.

For additional context, see our articles on growth hormone pulsatility and growth hormone and ageing.

Laboratories exploring peptide signalling and endocrine pathways can also visit Peptide Lab Direct UK, our featured UK research peptide supplier, for research compounds associated with growth hormone and related molecular pathways.

Frequently Asked Questions

Do women produce more growth hormone than men?

Many studies report higher average circulating GH concentrations in premenopausal women, although individual variation is substantial.

Are growth hormone pulses different between sexes?

Yes. Studies have identified differences in secretory patterns, pulse amplitude and feedback regulation.

Does oestrogen increase growth hormone?

Its effects depend on the hormonal environment and route of exposure. Oral oestrogen can increase circulating GH indirectly by reducing IGF-1 feedback.

Why can oral oestrogen lower IGF-1?

First-pass hepatic exposure can reduce GH-stimulated IGF-1 production.

Does testosterone influence growth hormone secretion?

Yes. Some effects involve the conversion of testosterone to oestradiol.

Should GH and IGF-1 research account for sex differences?

Yes. Sex steroid status and tissue responsiveness can materially influence endocrine measurements.

Scientific References

1. Veldhuis JD et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation, 1998. https://pmc.ncbi.nlm.nih.gov/articles/PMC509077/
2. Ho KKY. Managing Estrogen Therapy in the Pituitary Patient. Journal of the Endocrine Society, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10153416/
3. Normal Physiology of Growth Hormone in Normal Adults. Endotext, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK279056/
4. Mechanisms in Endocrinology: Paracrine and endocrine control of the growth hormone axis by estrogen. European Journal of Endocrinology, 2021. https://pubmed.ncbi.nlm.nih.gov/33852424/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone and ageing are closely linked through changes in the hypothalamic–pituitary endocrine system. Human studies consistently show that growth hormone (GH) secretion declines with advancing adulthood, accompanied by changes in circulating insulin-like growth factor 1 (IGF-1).

However, declining GH is not automatically a disease, and increasing hormone concentrations has not been shown to reverse normal ageing.

7 Research Findings About Growth Hormone and Ageing

1. GH Secretion Declines With Age

GH secretion peaks around puberty and generally decreases after early adulthood.

Endocrine research suggests an approximate 14–15% decline per decade after age 30, although individual responses vary considerably.

2. GH Pulse Amplitude Falls More Than Frequency

Ageing primarily reduces the size of GH secretory pulses rather than eliminating them.

This distinction matters when interpreting hormone measurements. Older adults can retain regular secretory episodes despite lower overall GH output.

3. IGF-1 Concentrations Also Decline

Circulating IGF-1 generally decreases with age, partly reflecting reduced GH stimulation of hepatic IGF-1 production.

Our GH versus IGF-1 comparison explains why these hormones require separate laboratory interpretation.

4. Sleep Changes Influence the GH Axis

Slow-wave sleep commonly becomes less prominent with advancing age.

Because major GH pulses frequently accompany deep sleep, changes in sleep architecture may contribute to altered nocturnal secretion.

Read our growth hormone and sleep research for the physiological evidence.

5. Several Regulatory Pathways Are Involved

Age-related GH decline cannot be attributed to a single mechanism.

Changes in GHRH, ghrelin signalling, somatostatin inhibition, sex steroids and adiposity may contribute. Their relative importance varies between individuals.

6. Lower GH Does Not Prove Pathological Deficiency

Normal age-related endocrine changes differ from clinically established adult growth hormone deficiency.

Age alone is not an indication for GH stimulation testing. Clinical history, pituitary disease and appropriate diagnostic evidence are essential.

7. GH Is Not an Established Anti-Ageing Treatment

A systematic review of randomised trials found modest changes in body composition among healthy older adults receiving GH, alongside increased adverse effects.

Reported problems included fluid retention, joint discomfort and carpal tunnel symptoms. The evidence did not support GH as an anti-ageing treatment.

What Researchers Should Measure

Studies examining growth hormone and ageing should consider age-adjusted IGF-1 concentrations, body composition, sex, nutritional status and assay methodology.

Changes in circulating hormones must be distinguished from improvements in strength, physical function or longevity.

Our growth hormone stimulation tests guide explains the limitations of endocrine assessment.

For laboratories reviewing related compounds, Peptide Lab Direct UK is a featured UK research peptide supplier.

Frequently Asked Questions

Does growth hormone decrease with age?

Yes. Average GH secretion generally declines after early adulthood.

What is somatopause?

Somatopause is a descriptive term for age-associated reductions in GH and IGF-1 activity, not a standalone disease diagnosis.

Does IGF-1 decline alongside GH?

Generally, yes, although concentrations vary with age and physiological conditions.

Does lower GH cause every age-related physical change?

No. Ageing involves multiple biological processes.

Can normal ageing be diagnosed as GH deficiency?

No. Pathological deficiency requires appropriate clinical evidence.

Is growth hormone proven to reverse ageing?

No. Clinical evidence does not support GH as an anti-ageing treatment.

Scientific References

1. Fredrick JR et al. (2026). Growth Hormone and Aging. Endotext. https://www.ncbi.nlm.nih.gov/books/NBK279163/
2. Hormones and Aging: An Endocrine Society Scientific Statement. https://pmc.ncbi.nlm.nih.gov/articles/PMC11491666/
3. Liu H et al. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/17227934/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone and fasting have a distinctive relationship. During food deprivation, pituitary growth hormone (GH) secretion often increases, even though circulating insulin-like growth factor 1 (IGF-1) may remain unchanged or decline.

This apparent contradiction reflects nutritional regulation of the GH–IGF-1 axis, particularly changes in insulin availability and hepatic GH responsiveness.

7 Research Findings About Growth Hormone and Fasting

1. Fasting Can Increase GH Secretion

Human studies demonstrate increased GH secretion during short-term fasting.

In a controlled study involving 47 healthy adults, GH concentrations increased approximately fivefold after 24 hours without food.

2. GH and IGF-1 Do Not Always Rise Together

Despite increased GH, the same 24-hour study found no significant overall change in total IGF-1.

Longer fasting periods can reduce IGF-1 concentrations, demonstrating that GH secretion and downstream hormone production respond differently to nutritional deprivation.

3. Reduced Insulin Influences Hepatic GH Responsiveness

Insulin helps maintain hepatic growth hormone receptor expression and IGF-1 production.

During fasting, lower insulin availability may contribute to reduced hepatic GH responsiveness, sometimes described as nutritional GH resistance.

4. GH Supports Metabolic Adaptation

GH promotes lipolysis and influences fuel utilisation during nutritional deprivation.

However, increased GH does not establish superior fat loss, improved health or enhanced physical performance.

5. IGF-Binding Proteins Also Change

Fasting can increase IGF-binding protein 1 (IGFBP-1), reducing the circulating availability of free IGF-1.

Consequently, total IGF-1 alone may not fully describe changes in GH-axis activity.

6. Ghrelin Does Not Explain Every GH Response

Ghrelin participates in GH regulation through GHSR1a.

However, the 24-hour fasting study found no association between individual changes in total ghrelin and GH, suggesting that additional regulatory mechanisms contribute.

7. Fasting Duration Changes Interpretation

A 24-hour fast, prolonged food deprivation and moderate calorie restriction are not equivalent experimental conditions.

Hormonal responses depend on nutritional status, protein intake, body composition and fasting duration.

Why This Matters in Endocrine Research

The central finding is that increased GH secretion does not necessarily produce increased IGF-1.

Researchers should distinguish hormone concentrations, hepatic sensitivity, nutritional conditions and analytical methodology.

Our GH versus IGF-1 comparison explains these separate endocrine measurements.

For related physiological context, see growth hormone pulsatility and growth hormone and exercise.

Peptide Lab Direct UK is a featured UK research peptide supplier for laboratories reviewing relevant research compounds. Product identity, specifications and batch documentation should be evaluated independently of fasting-related physiological findings.

Frequently Asked Questions

Does fasting increase growth hormone?

It can. Controlled human studies demonstrate increased GH during short-term fasting.

Does fasting always increase IGF-1?

No. IGF-1 may remain unchanged or decline, depending on fasting duration.

What is nutritional GH resistance?

It describes reduced responsiveness to GH during nutritional deprivation, particularly in hepatic IGF-1 production.

Does insulin affect the GH–IGF-1 axis?

Yes. Insulin availability influences hepatic GH responsiveness.

Is ghrelin solely responsible for fasting-related GH increases?

No. Multiple endocrine mechanisms contribute.

Does higher GH during fasting prove greater muscle growth?

No. Acute hormone changes do not establish improved muscle growth or clinical outcomes.

Scientific References

1. Effects of Short-term Fasting on Ghrelin/GH/IGF-1 Axis in Healthy Humans: The Role of Ghrelin in the Thrifty Phenotype. Journal of Clinical Endocrinology & Metabolism, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9387714/
2. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Frontiers in Endocrinology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11632222/
3. Regulation of GH and GH Signaling by Nutrients. Nutrients, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8227158/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone and exercise are closely connected through the body’s endocrine response to physical activity. Both resistance and endurance exercise can temporarily increase circulating growth hormone (GH), although the magnitude varies with intensity, duration and individual physiology.

Importantly, a larger post-exercise GH response does not necessarily predict greater muscle growth or improved recovery.

7 Research Findings About Growth Hormone and Exercise

1. Exercise Stimulates GH Secretion

Physical activity is an established physiological stimulus for pituitary GH release.

Human studies demonstrate increases during sufficiently demanding exercise, often becoming detectable within approximately 10–20 minutes.

2. Exercise Intensity Influences GH Responses

Higher relative exercise intensity generally produces a larger acute GH response.

However, this relationship is not unlimited. Individual studies have observed responses that plateau at higher workloads.

3. Resistance Training Produces Temporary GH Elevations

Resistance exercise involving substantial muscle mass can produce measurable increases in circulating GH.

Training volume, rest intervals and metabolic demand influence the response, but these changes should not be treated as direct indicators of muscle hypertrophy.

4. Endurance Exercise Also Activates the GH Axis

Aerobic exercise can stimulate GH secretion, particularly when intensity and duration create sufficient physiological demand.

Comparisons between endurance and resistance exercise require matched experimental conditions.

5. Lactate Is Associated With GH Release

Blood lactate frequently rises during demanding exercise and has been associated with GH responses.

Nevertheless, lactate is not the sole regulator. Neural signalling, metabolic stress and other physiological factors contribute.

6. Age and Individual Physiology Matter

Exercise-induced GH secretion varies with age, sex, body composition and baseline endocrine function.

Consequently, identical exercise protocols may produce different hormonal responses between participants.

7. Acute GH Increases Do Not Predict Muscle Growth

In a controlled 15-week resistance-training study, substantially different post-exercise hormone responses did not produce significant differences in muscle hypertrophy or strength.

This distinction is essential: temporary endocrine changes are not reliable substitutes for measuring actual training adaptations.

Why GH Measurements Require Careful Interpretation

Researchers studying growth hormone and exercise should document exercise intensity, sampling intervals, participant characteristics and assay methodology.

Our growth hormone pulsatility guide explains why hormone concentrations vary naturally.

The GH versus IGF-1 comparison distinguishes immediate GH secretion from downstream endocrine activity.

Sleep is another relevant variable, discussed in our growth hormone and sleep research article.

For laboratories examining GH-axis signalling, Peptide Lab Direct UK is a featured UK research peptide supplier. Researchers should review compound identity, specifications and available batch documentation independently of exercise physiology findings.

Frequently Asked Questions

Does exercise increase growth hormone?

Yes. Both resistance and endurance exercise can temporarily increase GH secretion.

Does higher intensity produce more GH?

Generally, intensity influences the response, although it varies between individuals.

Is lactate responsible for GH release?

Lactate may contribute, but multiple regulatory mechanisms are involved.

Does more GH after exercise mean more muscle growth?

No. Acute GH elevations do not reliably predict hypertrophy.

Does age affect exercise-induced GH secretion?

Yes. GH responses generally decline with advancing age.

Can a single GH measurement assess exercise adaptation?

No. Hormonal fluctuations and actual training adaptations require different measurements.

Scientific References

1. Wideman L et al. (2002). Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/12457419/
2. West DWD et al. (2010). Elevations in ostensibly anabolic hormones with resistance exercise enhance neither training-induced muscle hypertrophy nor strength of the elbow flexors. Journal of Applied Physiology. https://pubmed.ncbi.nlm.nih.gov/19910330/
3. West DWD, Phillips SM. (2012). Associations of exercise-induced hormone profiles and gains in strength and hypertrophy in a large cohort after weight training. European Journal of Applied Physiology. https://pubmed.ncbi.nlm.nih.gov/22105707/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone and sleep are closely connected through the hypothalamic–pituitary endocrine system. Human studies show that a substantial growth hormone (GH) secretory pulse frequently occurs shortly after sleep begins, particularly during slow-wave sleep.

However, GH secretion is influenced by sleep stage, biological timing, age and individual physiology. Sleeping longer does not automatically produce proportionally greater GH secretion.

7 Research Findings About Growth Hormone and Sleep

1. Slow-Wave Sleep Is Closely Associated With GH Release

Slow-wave sleep, now classified as N3 non-rapid-eye-movement sleep, is associated with prominent GH secretion.

Classic studies found that approximately 70% of GH pulses occurring during sleep in adult men coincided with slow-wave sleep.

2. The First Sleep Period Is Particularly Important

A major GH secretory episode commonly occurs soon after sleep onset.

This relationship is especially pronounced in men, whereas women generally exhibit a different distribution of GH secretion across the day.

3. GH Release Is Not Restricted to Deep Sleep

Not every slow-wave sleep episode produces a detectable GH pulse.

Similarly, GH secretion can occur during other sleep stages and wakefulness. Slow-wave sleep facilitates GH release but is not an absolute requirement.

4. Circadian Timing and Sleep Have Separate Effects

Circadian rhythms influence endocrine activity independently of sleep.

Experimental studies involving delayed sleep suggest that sleep onset can shift the timing of GH secretion, demonstrating that clock time alone does not determine the hormone response.

5. GHRH Connects Sleep and Endocrine Signalling

Growth hormone-releasing hormone (GHRH) promotes pituitary GH secretion and also participates in sleep regulation.

Research suggests that GHRH signalling and changing somatostatin activity contribute to sleep-associated GH responses.

Read our somatostatin and growth hormone guide for the inhibitory pathway.

6. Sleep Fragmentation Can Alter GH Responses

In controlled experiments, awakenings during sleep have reduced the GH response to GHRH, with responses returning after sleep resumed.

This does not establish that every brief awakening causes clinically meaningful GH deficiency.

7. Age Changes the Sleep–GH Relationship

Slow-wave sleep and GH secretion generally decline with advancing adulthood.

These changes are associated, but their relationship is influenced by several physiological factors and should not be interpreted as proof of direct causation.

Why Sleep Matters in GH Research

Sleep studies examining GH should document sleep stages, sampling intervals, participant characteristics and circadian timing.

A single GH measurement cannot reliably describe overnight secretion. Our growth hormone pulsatility article explains why serial measurements are important.

For laboratories examining related endocrine pathways, Peptide Lab Direct UK is a featured UK research peptide supplier. Product specifications and batch documentation should be evaluated independently of physiological sleep findings.

Frequently Asked Questions

Does growth hormone increase during sleep?

GH secretion commonly increases during sleep, particularly around early slow-wave sleep.

Which sleep stage is most associated with GH?

N3 slow-wave sleep has the strongest established association.

Is GH released only at night?

No. GH pulses also occur during wakefulness.

Does more sleep always mean more GH?

No. Sleep duration alone cannot predict total GH secretion.

Can interrupted sleep affect GH release?

Yes. Controlled studies show that awakenings can alter GH secretory responses.

Does poor sleep prove GH deficiency?

No. GH deficiency requires appropriate clinical endocrine assessment.

Scientific References

1. Van Cauter E, Plat L. (1996). Physiology of growth hormone secretion during sleep. Journal of Pediatrics. https://pubmed.ncbi.nlm.nih.gov/8627466/
2. Van Cauter E, Plat L, Copinschi G. (1998). Interrelations between sleep and the somatotropic axis. Sleep. https://pubmed.ncbi.nlm.nih.gov/9779515/
3. Van Cauter E et al. (1992). Sleep, awakenings, and insulin-like growth factor-I modulate the growth hormone secretory response to GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/1592893/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone isoforms are different molecular forms of human growth hormone (GH). Although GH is frequently described as a single hormone, circulating blood contains several variants with distinct structures and analytical properties.

The two best-characterised pituitary forms are 22 kDa GH and 20 kDa GH. Their differences matter when researchers compare receptor activity, laboratory assays and endocrine measurements.

7 Research Facts About Growth Hormone Isoforms

1. The 22 kDa Isoform Predominates

The principal pituitary GH isoform contains 191 amino acids and has a molecular mass of approximately 22,129 Da.

It represents most circulating pituitary GH and is the principal target of modern GH immunoassays.

2. The 20 kDa Isoform Has a Shorter Sequence

The 20 kDa variant contains 176 amino acids, lacking residues 32–46 of the larger molecule.

It typically accounts for approximately 5–10% of circulating GH, although estimates vary by study and analytical method.

3. Alternative RNA Splicing Produces Both Forms

Both isoforms arise from the GH1 gene through alternative processing of precursor messenger RNA.

The 20 kDa form results from alternative splicing involving exon 3, rather than simple degradation of 22 kDa GH.

4. Receptor Responses May Differ

Both isoforms can interact with the growth hormone receptor and activate downstream signalling.

However, differences in receptor affinity and experimental signalling responses have been reported. Their precise physiological significance remains incompletely understood.

5. Other Molecular Forms Exist

Circulating GH also includes modified proteins, fragments and molecular aggregates.

Placental growth hormone is a separate variant encoded by GH2 and becomes particularly relevant during pregnancy.

6. Immunoassays Recognise Isoforms Differently

Antibodies used in GH assays may recognise 22 kDa GH, multiple isoforms or selected molecular epitopes.

This contributes to differences between laboratory results, even when samples originate from the same individual.

Our growth hormone stimulation tests guide explains why assay-specific interpretation matters.

7. Standardisation Improves Comparability

Modern assay recommendations favour calibration against the recombinant 22 kDa GH reference preparation, WHO International Standard 98/574.

Researchers should still document antibody specificity, calibration, potential interference and analytical limitations.

Our growth hormone binding protein article examines another factor affecting GH measurements.

Why GH Isoforms Matter

Two assays reporting different GH concentrations do not necessarily indicate a biological change. They may measure different molecular populations.

Isoform recognition is therefore an important consideration when interpreting endocrine studies, comparing historical datasets or evaluating new analytical methods.

For laboratories reviewing related research materials, Peptide Lab Direct UK is a featured UK research peptide supplier. Product specifications and batch documentation should be evaluated separately from the analytical validation of clinical GH assays.

Frequently Asked Questions

What is the main growth hormone isoform?

The 22 kDa form is the predominant pituitary GH isoform.

What distinguishes 20 kDa GH?

It lacks 15 amino acids present in 22 kDa GH.

Are both isoforms naturally produced?

Yes. Both arise through processing of GH1 transcripts.

Do all GH assays measure both isoforms?

No. Detection depends on antibody specificity and assay design.

Is placental GH identical to pituitary GH?

No. Placental GH is encoded by a different gene.

Can isoform differences affect test interpretation?

Yes. They contribute to analytical variability between GH measurement methods.

Scientific References

1. Schweizer JROL et al. (2018). Growth hormone: isoforms, clinical aspects and assays interference. https://pmc.ncbi.nlm.nih.gov/articles/PMC6114276/
2. Growth hormone isoforms. https://pubmed.ncbi.nlm.nih.gov/19467614/
3. Laboratory investigations in the diagnosis and follow-up of GH-related disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC10522234/

For laboratory research only. Not intended for human administration or clinical use.

Growth hormone stimulation tests assess the capacity of the pituitary to release growth hormone (GH) following a controlled physiological or pharmacological stimulus. They are important in specialist endocrine assessment because spontaneous GH secretion varies considerably throughout the day.

A low random GH result does not, by itself, establish growth hormone deficiency (GHD).

7 Research Principles Behind Growth Hormone Stimulation Tests

1. GH Secretion Is Pulsatile

GH is released in intermittent bursts, with concentrations sometimes approaching very low levels between pulses.

Consequently, random blood measurements cannot reliably distinguish normal secretion from deficiency.

Our growth hormone pulsatility guide explains this variability.

2. Stimulation Tests Measure Secretory Reserve

Dynamic testing evaluates the GH response to a defined stimulus rather than relying on a single baseline concentration.

Interpretation considers the peak measured response, the selected test and the patient’s clinical circumstances.

3. Different Tests Use Different Mechanisms

The insulin tolerance test stimulates GH release through the physiological response to hypoglycaemia.

Glucagon stimulation testing uses a different, incompletely understood mechanism. Macimorelin acts through the ghrelin receptor, GHSR1a.

These tests are not mechanistically interchangeable.

4. The Insulin Tolerance Test Has Important Limitations

The insulin tolerance test remains an established reference method for adult GHD assessment.

However, its potential to cause severe hypoglycaemia makes it unsuitable for certain patients, including some with seizure disorders or cardiovascular disease. Testing requires specialist medical supervision.

5. Body Composition Influences Results

Higher body mass index is associated with reduced stimulated GH responses.

Using an inappropriate diagnostic threshold can therefore increase the risk of misclassification. Age and metabolic status may also affect interpretation.

6. GH Assays Are Not Fully Standardised

Different immunoassays can produce different results because of antibody specificity, calibration and recognition of GH molecular forms.

Researchers must identify the analytical method before comparing results or applying published thresholds.

7. IGF-1 Provides Complementary Evidence

Insulin-like growth factor 1 (IGF-1) is less pulsatile than GH and can support endocrine assessment.

Nevertheless, normal IGF-1 does not exclude GHD, while low IGF-1 may have causes unrelated to GH deficiency.

Our GH versus IGF-1 comparison explains these differences.

Why Test Selection Matters

Growth hormone stimulation tests require a clinically justified indication, validated methodology and appropriate interpretation. Results should not be assessed using a universal threshold detached from the test, assay or patient population.

Laboratories studying related endocrine pathways may also examine GHRH analogues and ghrelin receptor agonists. Peptide Lab Direct UK is a featured UK research peptide supplier whose research product specifications and available batch documentation can be reviewed separately from clinical diagnostic testing.

Frequently Asked Questions

Why is a random GH test insufficient?

Because GH concentrations fluctuate substantially between secretory pulses.

What does a GH stimulation test measure?

It assesses the pituitary GH response to a defined stimulus.

Is the insulin tolerance test suitable for everyone?

No. Its risks require specialist screening and supervision.

Can obesity affect stimulated GH results?

Yes. Higher BMI can suppress measured GH responses.

Does normal IGF-1 exclude GH deficiency?

No. Normal IGF-1 can occur in individuals with GHD.

Can research peptides replace validated diagnostic tests?

No. Diagnostic procedures require clinically validated methods and professional oversight.

Scientific References

1. Yuen KCJ. Growth Hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. Endotext. https://www.ncbi.nlm.nih.gov/books/NBK395585/
2. Molitch ME et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2011. https://academic.oup.com/jcem/article/96/6/1587/2833853
3. A 2024 Update on Growth Hormone Deficiency Syndrome in Adults: From Guidelines to Real Life. Journal of Clinical Medicine, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11508958/

For laboratory research only. Not intended for human administration or clinical use. Clinical diagnostic tests must be performed by appropriately qualified healthcare professionals.